A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease
Authors:
- 1 February 2018
- journal article
- review article
- Published by Taylor & Francis in Immunotherapy
- Vol. 10 (2) , 107-117
Abstract
The introduction of biological agents has led to significant changes in the treatment of inflammatory bowel disease (IBD). The relatively high price of infliximab (IFX) and the expiration of the patents led to the introduction of biosimilar agents. CT-P13 was the first IFX biosimilar approved in the same indications as the reference product; however, the approval was based on randomized clinical trials conducted in patients with rheumatoid arthritis and ankylosing spondylitis. In the past 2-3 years, new findings from prospective observational studies supported the short-, medium-and long-term clinical efficacy and safety of CT-P13 in patients with IBD. This review summarized the clinical use and efficacy of the first biosimilar IFX, CT-P13, in the treatment of IBD.Keywords
Funding Information
- National Research, Development and Innovation Office (119809, 125377, EFOP-3.6.2–16–2017–00006)
- New National Excellence Program of the Ministry of Human Capacities
This publication has 53 references indexed in Scilit:
- Biosimilars: the science of extrapolationBlood, 2014
- The challenge of indication extrapolation for infliximab biosimilarsBiologicals, 2014
- Have Biologics Changed the Natural History of Crohn's Disease?Digestive Diseases, 2014
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnnals of the Rheumatic Diseases, 2013
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA studyAnnals of the Rheumatic Diseases, 2013
- Biosimilars: what clinicians should knowBlood, 2012
- Biologicals and biosimilars: a review of the science and its implicationsGenerics and Biosimilars Initiative Journal, 2012
- Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic ReviewGastroenterology, 2012
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002